Infections in Patients with Leukemia and Lymphoma

Morrison, Vicki A.

doi:10.1007/978-3-319-04220-6_11

Cited by 47 publications

(52 citation statements)

References 190 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Infectious complications are a well‐recognized major cause of morbidity and mortality in CLL, given the humoral immunodepression inherent to the disease and therapy‐induced immunosuppression . Similar to other BCRPIs, infections, particularly pneumonias and URTIs, were frequently observed and remain an important risk .…”

Section: Discussionmentioning

confidence: 99%

Duvelisib, an oral dual PI3K‐δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study

et al. 2018

View full text Add to dashboard Cite

Duvelisib (IPI-145), an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-δ and -γ, was evaluated in a Phase 1 study in advanced hematologic malignancies, which included expansion cohorts in relapsed/refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and treatment-naïve (TN) CLL. Per protocol, TN patients were at least 65 years old or had a del(17p)/TP53 mutation. Duvelisib was administered twice daily (BID) in 28-day cycles at doses of 8-75 mg in RR patients (n = 55) and 25 mg in TN patients (n = 18.) Diarrhea was the most common nonhematologic AE (TN 78%, RR 47%); transaminase elevations the most frequent lab-abnormality AE (TN 33.3%, RR 30.9%); and neutropenia the most common ≥grade 3 AE (RR 44%, TN 33%). The overall response rates were 56.4% for RR patients (1.8% CR, 54.5% PR) and 83.3% for TN patients (all PRs); median response duration was 21.0 months in RR patients but was not reached for TN patients. Based upon phase 1 efficacy, pharmacodynamics, and safety, duvelisib 25 mg BID was selected for further investigation in a phase 3 study in RR CLL/SLL.

show abstract

Section: Discussionmentioning

confidence: 99%

Duvelisib, an oral dual PI3K‐δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study

et al. 2018

View full text Add to dashboard Cite

show abstract

“…38 Malignant lymphomas and CLL significantly increase the risk for serious infections. 39,40 The cause of this increased risk for infections is multifactorial. Early on, the humoral immune abnormalities, resulting from B-lymphocyte dysfunction often accompanied by the emergence of hypogammaglobulinemia, dominate, and infections are caused mainly by viruses and encapsulated bacteria.…”

Section: Infections In Patients With Lymphoid Malignanciesmentioning

confidence: 99%

'Trained immunity: consequences for lymphoid malignancies

et al. 2016

View full text Add to dashboard Cite

© Ferrata Storti Foundationhave no adaptive immune response, e.g., plants and invertebrates, but it also exists in humans, where it might be of special benefit in neonates that have yet to develop a mature adaptive immune repertoire.6 Importantly, 'training' of the innate immune system by the use of vaccination, resulting in increased immune activation, has been shown feasible. Hopefully these insights can be exploited in the near future for the design of new treatments for immunodeficiencies, infections and cancer.

show abstract

“…Infections account for up to 60% of deaths in patients with CLL. 1 To lessen infectious complications, immunization against influenza for immunocompromised individuals is recommended. 2 However, patients with CLL have impaired responses to vaccines, which are further reduced by hypogammaglobulinemia and chemotherapy.…”

mentioning

confidence: 99%

Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib

et al. 2016

View full text Add to dashboard Cite

are warranted to evaluate whether ibrutinib impairs or improves vaccine response relative to other treatments.Limitations of the study include a small sample size and incomplete laboratory confirmation of influenza infection. Furthermore, defining an appropriate control group may prove challenging; treatment-naive patients often have immune impairment related to their disease while patients in remission after chemoimmunotherapy may experience the immunosuppressive effects of treatment. 7

show abstract

Infections in Patients with Leukemia and Lymphoma

Cited by 47 publications

References 190 publications

Duvelisib, an oral dual PI3K‐δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study

Duvelisib, an oral dual PI3K‐δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study

'Trained immunity: consequences for lymphoid malignancies

Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib

Contact Info

Product

Resources

About